Skip to main content
. Author manuscript; available in PMC: 2007 Oct 1.
Published in final edited form as: Exp Neurol. 2007 Feb 14;205(1):92–100. doi: 10.1016/j.expneurol.2007.01.038

Fig. 4.

Fig. 4

The NK1 and NK3 agonists do not increase firing in phasic DRG neurons. A, A NK3-selective agonist, [MePhe7]-neurokinin B (NKB, 0.5 μM, bottom trace) did not change firing (top trace, control). Firing in response to a current injection 600 ms long and 250 pA in intensity. B, Average firing before and after NKB in 5 neurons. C, An NK1-selective agonist, [Sar9, Met11]-substance P (SarMetSP, 0.5 μM, bottom trace) did not change firing (top trace, control). Firing in response to a current injection 600 ms long and 250 pA in intensity. D, Average firing before and after SarMetSP in 5 neurons.